Matrix metalloproteinase-3 as a marker of subclinical activity in rheumatoid arthritis patients: Relation to ultrasonographic activity

被引:4
|
作者
Hamdy, Fatma [1 ]
Morad, Nibal [1 ]
Tharwat, Samar [1 ]
Abd El-khalek, Ahmed [2 ]
Mahsoub, Nancy [3 ]
Eltoraby, Ehab [1 ]
Enein, Asmaa [1 ]
机构
[1] Mansoura Univ, Fac Med, Internal Med Dept, Rheumatol & Immunol Unit, Dakahlia, Egypt
[2] Mansoura Univ, Fac Med, Diagnost Radiol Dept, Dakahlia, Egypt
[3] Mansoura Univ, Fac Med, Clin Pathol Dept, Dakahlia, Egypt
来源
EGYPTIAN RHEUMATOLOGIST | 2022年 / 44卷 / 03期
关键词
Rheumatoid arthritis; Remission; Subclinical activity; Matrix metalloproteinase-3; Sonographic activity; DISEASE-ACTIVITY;
D O I
10.1016/j.ejr.2021.12.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rheumatoid arthritis (RA) isa chronic disease which may result in progressive joint destruc-tion even with clinical remission. Ultrasound (US) can detect subclinical disease activity and matrix met-alloproteinase 3 (MMP-3) has a role in disease activity in RA. Aim of the work: To evaluate the level of MMP-3 in RA patients and its ability to predict sonographic activ-ity in patients with clinical remission or low disease activity (LDA). Patients and methods: This study included 45 RA patients with a disease activity score (DAS28) <3.2 and 45 matched healthy control. US evaluation using modified German US7 score was performed and accord-ingly patients were classified into those with sonographic remission (grey scale 0-1) or activity. MMP-3 level was assessed by enzyme-linked immunosorbent assay. Results. The mean age of the patients was 45 +/- 9.5 years and 86.7% were females. Sonographic remission was achieved in 20 (44.4 %) patients. There was a significant difference in serum MMP-3 between patients and control (17 +/- 4.5 vs 6.3 +/- 2.2 ng/ml; p < 0.0001). There was no difference between patients with clinical remission (n = 37) and those with LDA (n = 8). Serum MMP-3 tended to be higher in patients with sono-graphic activity than in those with sonographic remission (18 +/- 5.3 vs 15.6 +/- 2.8 ng/ml; p = 0.3). Serum MMP-3 significantly correlated with erythrocyte sedimentation rate (p = 0.002) and synovitis score (p = 0.002). Conclusion: Serum MMP-3 was higher in RA patients than in control and was associated with the ultra -sound synovitis score. However, serum MMP-3 was not able to differentiate patients with sonographic remission from those with subclinical activity. (c) 2022 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:261 / 265
页数:5
相关论文
共 50 条
  • [21] Matrix Metalloproteinase 3: A Biomarker of Disease Activity in Rheumatoid Arthritis.
    Reuter, Sandra
    Matthias, Torsten
    Larida, Bruno
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S900 - S900
  • [22] Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis:: comparison with traditional markers
    Ates, Askin
    Turkcapar, Nuran
    Olmez, Umit
    Tiryaki, Olcay
    Duzgun, Nursen
    Uguz, Emre
    Duman, Murat
    RHEUMATOLOGY INTERNATIONAL, 2007, 27 (08) : 715 - 722
  • [23] Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers
    Aşkın Ateş
    Nuran Türkçapar
    Ümit Ölmez
    Olcay Tiryaki
    Nurşen Düzgün
    Emre Uğuz
    Murat Duman
    Rheumatology International, 2007, 27 : 715 - 722
  • [24] SERUM MATRIX METALOPROTINASE 3 AS A MARKER TO DISCRIMINATE SUBCLINICAL DISEASE ACTIVITY FROM ULTRASOUND DEFINED REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Hamdy, F.
    Enein, A. F.
    Morad, N.
    Tharwat, S.
    Abd el-Khalek, A. M.
    Eltoraby, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 477 - 477
  • [25] MATRIX METALLOPROTEINASE-3 IS A GOOD PREDICTOR FOR JOINT DESTRUCTION ONLY IN MALE PATIENTS WITH RHEUMATOID ARTHRITIS
    Yamada, Y.
    Inui, K.
    Okano, T.
    Orita, K.
    Sugioka, Y.
    Mamoto, K.
    Koike, T.
    Tada, M.
    Nakamura, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1338 - 1339
  • [26] Serum matrix metalloproteinase-3 levels monitor the therapeutic efficacy in Syrian patients with rheumatoid arthritis
    Hussein, Rama
    Aboukhamis, Imad
    HELIYON, 2023, 9 (03)
  • [27] Elevated matrix metalloproteinase-3 level may affect hearing function in patients with rheumatoid arthritis
    Nasution, Muhammad Edy Syahputra
    Haryuna, Tengku Siti Hajar
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2019, 82 (04) : 272 - 276
  • [28] Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis
    Ling Zhou
    Geng Wang
    Xin Liu
    Jing Song
    Ling Chen
    Huji Xu
    Arthritis Research & Therapy, 19
  • [29] Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis
    Zhou, Ling
    Wang, Geng
    Liu, Xin
    Song, Jing
    Chen, Ling
    Xu, Huji
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [30] MATRIX METALLOPROTEINASE-3 LEVELS IN RHEUMATOID ARTHRITIS AND ITS RELATIONSHIP WITH OTHER DISEASES
    Tuncer, T.
    Kaya, A.
    Gulkesen, A.
    Kal, G. A.
    Akgol, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1000 - 1000